Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi Therapeutics (MGX) Change in Account Payables (2023 - 2025)

Metagenomi (MGX) has disclosed Change in Account Payables for 3 consecutive years, with $346000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 113.46% to $346000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 195.3% year-over-year, with the annual reading at $1.1 million for FY2025, 195.3% up from the prior year.
  • Change in Account Payables for Q4 2025 was $346000.0 at Metagenomi, up from -$1.6 million in the prior quarter.
  • The five-year high for Change in Account Payables was $3.2 million in Q1 2024, with the low at -$2.6 million in Q4 2024.
  • Average Change in Account Payables over 3 years is -$11333.3, with a median of -$98000.0 recorded in 2024.
  • The sharpest move saw Change in Account Payables soared 162.16% in 2024, then crashed 483.7% in 2025.
  • Over 3 years, Change in Account Payables stood at -$2.5 million in 2023, then dropped by 1.86% to -$2.6 million in 2024, then skyrocketed by 113.46% to $346000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $346000.0, -$1.6 million, and $74000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.